Eli Lilly considers copying Novo Nordisk's semaglutide branding strategy
Novo Nordisk branded the GLP-1 analog, semaglutide, under different names for respective treatments of obesity and diabetes. Now, Eli Lilly is chewing over a similar move for tirzepatide.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Novo Nordisk has a history of marketing drugs under different names for treatments of obesity and diabetes, respectively. Novo Nordisk's biggest competitor, Eli Lilly, is now pondering a similar move, writes industry media Fiercepharma.
All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.